Selim Arcasoy, MD
Pulmonary Disease · New York, NYNPI 1952488256
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by AstraZeneca at 53.3% of the total. Reporting peaked in 2020 at $454 and has fallen 83.0% since, to $77 in 2025. That places this record below the midpoint for pulmonary disease clinicians in NY, where the typical reported total is $756.
Across 8 payments — averaging $99.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$425
- Xvivo Perfusion Inc.$136
- Paragonix Technologies, Inc.$122
- La Jolla Pharmaceutical Company$72
- Insmed, Inc.$15
- Astellas Pharma US Inc$13
- plus $13 from 1 others
Across 8 payments — averaging $10,095 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$81K
What the payments were for
- Consulting fees$42553%
- Food & beverage$36045%
- Education$132%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $425 |
| Xvivo Perfusion Inc. | 2 | $136 |
| Paragonix Technologies, Inc. | 1 | $122 |
| La Jolla Pharmaceutical Company | 1 | $72 |
| Insmed, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SherpaPak$122
- LIVERguard$122
- LUNGguard$122
- BaroGuard$122
- PancreasPak$122
How this compares
$797 in reported general payments places this provider in the 50th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sodium Chloride0.9 % Sodium Chloride | 19 | $502 |
| Prednisone | 32 | $194 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.